2022 World Conference on Lung Cancer (ePosters)-EP08.02-003. Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis

EP08.02-003. Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis

Back to course

Pdf Summary

A study was conducted to evaluate the efficacy of aumolertinib, a novel third-generation oral tyrosine kinase inhibitor, in combination with chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) that harbors mutated EGFR. The study aimed to determine if this combination therapy could improve outcomes compared to first-generation EGFR inhibitors combined with chemotherapy.<br /><br />The primary endpoint of the study was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. A total of 42 patients were enrolled in the study, and the analysis was conducted up until November 2021.<br /><br />The results showed that the combination therapy of aumolertinib with chemotherapy had a high objective response rate of 88.2% in all patients. The ORR was higher in patients with EGFR exon19 deletion mutation (94.7%) compared to those with L858R mutation (80.0%). Patients with TP53 mutation also showed a higher ORR (92.3%). ctDNA clearance, which indicates a better treatment response, was observed in 90.9% of patients after 2-4 cycles of aumolertinib treatment.<br /><br />In terms of safety, the combination therapy was generally well-tolerated, with most adverse events being mild and manageable with symptomatic treatment. The most common adverse events included neutropenia, fatigue, and anorexia.<br /><br />The study concluded that the combination of aumolertinib and chemotherapy showed promise as a therapeutic strategy for advanced EGFR-mutated NSCLC, even in patients with central nervous system (CNS) metastasis. The data also suggested that patients with EGFR exon19 deletion mutation and TP53 mutation may benefit more from this combination therapy. Additionally, ctDNA clearance after 2-4 cycles of treatment was associated with a better treatment response.<br /><br />Overall, this study provides evidence for the potential efficacy of aumolertinib in combination with chemotherapy as a first-line treatment option for patients with advanced EGFR-mutated NSCLC. Further research and larger studies are needed to confirm these findings.

Asset Subtitle

YanWei Li

Meta Tag

Speaker YanWei Li

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

aumolertinib

oral tyrosine kinase inhibitor

chemotherapy

non-small cell lung cancer

NSCLC

EGFR mutation

progression-free survival

objective response rate

disease control rate

overall survival